Additionally, patients with low PlGF levels showed a trend toward increased adverse events compared to CHD women with non-reduced PlGF (66.7% vs 23.1%; P = 0.060; Figure 3B), and those with a high sFlt-1/PlGF ratio also demonstrated a similar trend (62.5% vs 20.8%; P = 0.072; Figure 3C). This evidence concerns the gene PGF and coronary artery disorder.